A Study of DS-2248 in Participants With Advanced Solid Tumors

Status Terminated

Clinical Trial Summary

This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in the blood and to understand the safety, tolerability and any effect of the drug on the tumor. The antitumor effect of the drug is not known in human.

Clinical Trial Description

The study will be conducted in two parts. Part 1 is a dose escalation study in which subjects in each cohort will be given increasing doses of the study drug until a maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined as the recommended phase 2 dose (RP2D). The drug will be administered as oral capsules once daily in 21 day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed. After determining the RP2D, Part 2 of the study, which is a dose expansion study will begin in which subjects with advanced non-small cell lung cancer who developed acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI), erlotinib, gefitinib, afatinib (and others) or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, will be treated with DS-2248 at RP2D. The drug will be administered as oral capsules once daily in 21 day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01288430
Study type	Interventional
Source	Daiichi Sankyo, Inc.
Contact
Status	Terminated
Phase	Phase 1
Start date	March 29, 2011
Completion date	February 13, 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00750841` - Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours	Phase 1
Withdrawn	`NCT05419817` - Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System	Phase 2
Completed	`NCT02828930` - A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)	Phase 1
Completed	`NCT01197170` - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	Phase 1
Terminated	`NCT03225105` - M3541 in Combination With Radiotherapy in Solid Tumors	Phase 1
Completed	`NCT03258515` - A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers	Phase 1
Completed	`NCT01497925` - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT01878890` - Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.	Phase 1
Active, not recruiting	`NCT05059522` - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	Phase 3
Active, not recruiting	`NCT03634982` - Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors	Phase 1
Recruiting	`NCT04685226` - A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Recruiting	`NCT06036121` - A Study of ADRX-0706 in Select Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03258151` - Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Completed	`NCT01528046` - Metformin in Children With Relapsed or Refractory Solid Tumors	Phase 1
Recruiting	`NCT05325866` - A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression	Phase 1/Phase 2
Recruiting	`NCT04557449` - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors	Phase 1/Phase 2
Completed	`NCT02759640` - A Phase I Trial of HS-10241 in Solid Tumors	Phase 1
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Withdrawn	`NCT01940601` - Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors	Phase 2